Zachary J. Roberts
President, CEO & DirectorDr. Zachary J. Roberts, also known as Zach, M. D., Ph. D., serves as President, CEO & Director at Allogene Therapeutics, Inc. since July 1, 2026. Dr. Roberts served as Chief Medical Officer at Allogene Therapeutics, Inc. since April 2023 until July 1, 2026 and was its Executive Vice President of Research and Development since January 2023 until July 1, 2026. Dr. Roberts joined the Allogene Therapeutics, Inc. in January 2023. He was Chief Medical Officer at Instil Bio, Inc. since March 2020 until November 11, 2022. Prior to joining, he served in various roles for Kite Pharma, Inc./Gilead Sciences, as Vice President, Clinical Development from February 2018 to May 2019. He was instrumental in the development and execution of the ZUMA trials across multiple indications for Yescarta(R), the first autologous CAR T therapy approved for non-Hodgkin's lymphoma. Prior to joining Kite, Dr. Roberts served as Clinical Research Medical Director for Amgen Oncology from January 2015 to July 2015. Dr. Roberts completed his clinical and post-graduate training in internal medicine and hematology/oncology at the Massachusetts General Hospital and Dana Farber Cancer Institute. Dr. Roberts is a trained immunologist and a Board certified oncologist with extensive experience in clinical oncology, including the development of cell therapies. He earned his B. S. in microbiology and immunology from the University of Maryland, College Park and both his Ph. D. in immunology and his M. D from the University of Maryland, Baltimore.
Positions
- Company NameAllogene Therapeutics, Inc.Stock CodeALLOPositionPresident, CEO & Director
